Publications by authors named "J Kolstad"
Article Synopsis
- GM1-gangliosidosis (GM1) causes significant brain degeneration, making it difficult to use automated MRI techniques for brain volume analysis. An effective standardized segmentation protocol was created to analyze MRIs from patients with type II GM1.
- A study involving 25 MRIs from 22 patients assessed the reliability of this segmentation method, focusing on various brain structures and evaluating the consistency between different raters.
- Results showed that the technique had good inter- and intra-rater reliability, especially for juvenile patients, which can enhance future research and understanding of the disease's progression over time.
Article Synopsis
- * Outcomes showed that 80% of aneurysms treated with SEAL Arc achieved complete occlusion, significantly higher than the 21% for WEB, alongside better neointimal coverage (86% vs. 49%).
- * Histological results indicated that all aneurysms treated with SEAL Arc were completely healed, suggesting the device is a promising option for early aneurysm treatment.
Article Synopsis
- * Researchers created a mouse model using CRISPR/Cas9 to study the disease, which mimics characteristics seen in human patients, such as specific gait abnormalities and a reduction in motor skills over time.
- * The Glb1 mice also display progressive brain atrophy and increased levels of a pentasaccharide biomarker, supporting their relevance for developing new treatments for GM1 gangliosidosis, particularly the less severe type II variant.
The COVID-19 pandemic has led to substantial increases in the use of telehealth and virtual care in the US. Differential patient and provider access to technology and resources has raised concerns that existing health disparities may be extenuated by shifts to virtual care. We used data from one of the largest providers of employer-sponsored insurance, the California Public Employees' Retirement System, to examine potential disparities in the use of telehealth.
View Article and Find Full Text PDFArticle Synopsis
- Tissue hypoxia is a major factor in cell death during ischemic stroke, and while inhaled oxygen showed potential in preliminary studies, it hasn't improved outcomes in larger trials.
- This study examined a new intravenous oxygen carrier (OMX-IS) aimed at selectively delivering oxygen to severely ischemic areas in a canine model, testing its ability to slow down the progression of stroke damage.
- Results showed that in fast-stroke progressors, OMX-IS significantly delayed infarct progression (by about an hour) and reduced final infarct size, while effects were less pronounced in slow progressors, indicating potential for this targeted approach.